Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth Launch Agreement with Philips for Prognostic Prostate Cancer Biomarker - MDxHealth announces worldwide licencing agreement with Philips for prognostic prostate cancer biomarker - Philips.com / MDxHealth.com
MDxHealth Launch Agreement with Philips for Prognostic Prostate Cancer Biomarker

 

PRZOOM - /newswire/ - Herstal, Belgium, 2018/06/06 - MDxHealth announces worldwide licencing agreement with Philips for prognostic prostate cancer biomarker - Philips.com / MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• MDxHealth announces worldwide licencing agreement with Philips for prognostic prostate cancer biomarker;
• Agreement with Philips facilitates the launch of InformMDx™.

MDxHealth SA ("MDxHealth, or the "Company"), today announces a worldwide licencing agreement with Koninklijke Philips N.V. ("Philips") (philips.com) for the rights to manufacture and market Philips' recently validated prognostic biomarker for prostate cancer, phosphodiesterase-4D7 ("PDE4D7"), as a prognostic test. The test is based on technology which was jointly developed by Philips Research and The University of Glasgow.

The agreement enables MDxHealth to prepare the launch of its InformMDx™ test for prostate cancer, a tissue-based test utilising PDE4D7 that can stratify patients according to their risk of disease progression and the development of secondary tumors. The Company anticipates that InformMDx will provide actionable information to help clinicians guide post-biopsy treatment decisions at the time of diagnosis, as well as post-surgical treatment decisions following prostatectomy. In the US alone, over 150,000 patients per year could benefit from the InformMDx test.

PDE4D7 has recently been validated in a 503 patient study published in the journal European Urology Focus which confirmed, based on 10-15 years of follow-up data, the independent prognostic and incremental value of PDE4D7 compared to the established clinical risk metric (eu-focus.europeanurology.com)

The financial terms of the agreement have not been disclosed.

Dr. Jan Groen, Chief Executive Officer of MDxHealth, commented: "This is an exciting deal which moves us a step closer towards launching InformMDx, our fourth commercial test which we believe will be valuable in providing physicians with critical information required to make informed therapeutic decisions for men recently diagnosed with Prostate Cancer. In line with our growth strategy, MDxHealth will continue to expand the range and reach of our diagnostic offering as the demand for actionable and cost-effective diagnosis and patient-monitoring grows across healthcare systems globally."

About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company, listed at the Brussels, Belgium, stock exchange (Euronext Brussels: MDXH.BR), that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.

The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

Contacts:
Consilium Strategic Communications (IR & PR)
Amber Fennell, Chris Welsh & Hendrik Thys
P: +44(0)20 3709 5701 - E: mdxhealth[.]consilium-comms.com.

Leon Melens - LifeSpring Life Sciences Communication
P: +31 6 538 16 427 - E: lmelens[.]lifespring.nl.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, InformMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth Launch Agreement with Philips for Prognostic Prostate Cancer Biomarker

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
InformMDx™ | Philips
Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From MDxHealth, Inc. / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Bruker Launches Revolutionary High-Speed AFM System for Single-Molecule Applications
Bruker Launches Second-Generation FluoroType® SARS-CoV-2 plus PCR Test for Detection of SARS-CoV-2 Viral Infections in Europe
SCHOTT Launches New VisiLED UV Ring Light for Stereo Microscopy
Citizen Care Pod Corp. Collaborates with WZMH Architects, PCL Construction, Insight Enterprises and Microsoft to Launch A Custom Mobile Testing Unit
American Regent Inc. Selects Sparta Systems’ TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network
Frost & Sullivan Analyzes the Future of Adhesion Prevention Products in the US and EU5
FORA Auto Temperature Measurement Station Provides Protection During COVID-19
TPEs Introduces A Range of TPE-compounds for Direct Contact with Blood and Body Fluid Applications in the Medical Sector
Safran and Segula Technologies Continue to Support the Fight Against Covid-19 by Adapting Decathlon’s Easybreath Subea Mask for Use in Hospitals
Bruker Partners with ANPC to Support Major New Frontline Response to Combat the COVID-19 Threat

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today